Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa is converted to dopamine in the brain, restoring deficient neurotransmission. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the central nervous system. Entacapone inhibits the COMT enzyme, slowing peripheral metabolism of levodopa and extending its plasma half‑life, which together provide more stable dopaminergic stimulation.

The appropriate dose of Lecigon is individualized by the prescribing clinician based on the patient's disease stage, response to levodopa, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects.

Safety of Lecigon in pregnancy and lactation has not been established. Because the effects on the fetus or infant are unknown, it is generally advised to avoid use unless the potential benefit justifies the potential risk, and only under close medical supervision.

To order Lecigon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Standard levodopa/carbidopa provides dopamine replacement but is limited by rapid peripheral metabolism, leading to motor fluctuations. Adding entacapone, as in Lecigon, inhibits COMT, prolonging levodopa plasma levels and reducing off‑time. This often results in smoother symptom control without increasing the levodopa dose.

Lecigon should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct light. Keep out of reach of children and do not use after the expiry date.

Lecigon is taken orally, usually with a glass of water. It can be taken with or without food, but consistent timing relative to meals helps maintain stable drug levels. Patients should follow the prescriber’s instructions regarding dosing frequency and any dose‑timing adjustments.

Serious risks include severe liver injury, neuroleptic malignant syndrome, and psychiatric complications such as suicidal thoughts or severe depression. Patients should be monitored regularly for hepatic function, changes in mood or behavior, and any signs of hyperthermia or muscle rigidity, and seek immediate medical attention if these occur.

Lecigon is contraindicated in patients with narrow‑angle glaucoma, those currently taking non‑selective MAO inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with a history of severe psychiatric disorders, uncontrolled hypertension, or significant cardiovascular disease.